News

Molecular Devices and Cytena Partner to Launch the CloneSelect Single-Cell Printer

Announcing the Single-Cell Printer for documented isolation of cells in clonal cell line development

Sunnyvale, California and Freiburg, Germany – September 19, 2017 – Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. This novel system utilizes sophisticated microfluidics-based technology and real-time image analysis to isolate single cells and provide visual documentation of monoclonality for use in cell line development.
Clonal cell line development has been receiving increasing focus and investment as a method for producing targeted therapeutics. As a part of the development process, cells producing high amounts of the antibody of interest need to be selectively isolated to be able to move them forward for additional screening. The CloneSelect SCP accelerates antibody discovery by allowing for automated isolation of single cells into standard 96- and 384- well plates for a wide range of cell types.

“We are very excited about this product and how it allows us to expand our toolset in the fast-growing biotherapeutics market,” said Greg Milosevich, President at Molecular Devices. “Our customers have been seeking ways to bring biologics and biosimilars to market more quickly, and we continue to invest in technologies that accelerate time-consuming process steps.”

Traditional methods for single cell sorting in cell line development suffer from drawbacks including low sorting efficiencies, low cell viabilities, and limited evidence of monoclonality. The CloneSelect SCP overcomes these limitations by screening for both single cells and for cell morphology immediately prior to gently depositing in the well, ensuring high cell viability. The use of sterilized, disposable cartridges also ensures the prevention of any cross-contamination or need for in-situ sterilization. During deposition, images of single cells are provided, giving customers the confidence of knowing their cell lines are monoclonal.

“This partnership will accelerate the continued growth of our business,” said Jonas Schoendube, CEO at Cytena. “We are looking forward to having additional commercial capabilities in the United States and Canada as a result of our work with Molecular Devices, and we believe that this relationship will bring superior service to our customer base.”

About Molecular Devices, LLC
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables and is dedicated to helping customers unravel the complexity of biological systems. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These innovative instruments, combined with scientific expertise, assays, and analytics tools for protein and cell biology enable scientists to explore life’s most important questions. The company is headquartered in Silicon Valley, California with offices around the globe.

About cytena, GmbH
Cytena GmbH is an established start-up in the field of life science, founded in 2014 in Freiburg, Germany and focuses on single-cell technologies. The Cytena team has developed the patented single-cell printing technology that enables deposition of single cells in a documented, viable and sterile workflow. The Single-Cell Printers™ are manufactured in Germany and marketed worldwide. In 2017, the majority of the top ten pharma companies use Single-Cell Printers to ensure fast antibody development.

For more information, visit: www.moleculardevices.com/CloneSelectSCP
or www.cytena.com

Contact Information for Molecular Devices:
Sarah Vargas-Hurlston
Director of Marketing, Drug Discovery
+1 408.203.8692
sarah.vargas-hurlston@moldev.com

Contact Information for Cytena GmbH:
Benjamin Steimle
CFO
+49 761 203 732 19
steimle@cytena.com

Read the press release: PDF

Read more:

 

Go back